GlobeNewsWire
08 Jul 2026, 13:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
MAIA Biotechnology's Phase 2 THIO-101 Part C expansion trial reported a 90.5% disease control rate (DCR) for third-line advanced non-small cell lung cancer. — A 90.5% DCR is significantly higher than the reported 25-35% for standard-of-care chemotherapy, suggesting high potential for the lead candidate.
+0.80The positive results were observed in a heavily pre-treated patient population resistant to both immunotherapy and chemotherapy. — Efficacy in resistant, late-stage populations increases the potential addressable market and clinical value of the drug.
+0.60Ateganosine followed by cemiplimab has demonstrated an acceptable safety profile in the trial population to date. — Safety is a prerequisite for regulatory approval; an acceptable profile removes a major binary risk for the asset.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
MAIA has completed international enrollment for Part C of the Phase 2 THIO-101 expansion trial. — Completion of enrollment indicates the trial is moving toward the final data analysis phase, reducing timeline uncertainty.
+0.20Which stocks this story touches
The company reported strong initial efficacy data with a 90.5% disease control rate in its Phase 2 clinical trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1d ago
